Log In
Print
BCIQ
Print
Print this Print this
 

MK-8931, SCH 900931

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Molecular Target Beta-site APP-cleaving enzyme 1 (BACE1)
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD); Treat mild to moderate Alzheimer's disease (AD); Treat prodromal Alzheimer's disease (AD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today